An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib

作者：Zhang, Ying^*; Tang, Huaping; Li, Jun; Li, Meng

来源：OncoTargets and Therapy, 2015, 8: 1351.

DOI：10.2147/OTT.S78925

• EGFR
• non-small cell lung cancer
• tyrosine kinase inhibitor

Lung cancer has the highest mortality rate of all cancers world-wide. A total of 70%-75% of all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with locally advanced or metastatic disease at diagnosis. Brain metastasis is one of the most common problems in the management of NSCLC, worsening the prognosis and quality of life of NSCLC patients. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. Icotinib is a new type of oral EGFR-TKI. In this report, we describe a patient with lung adenocarcinoma cancer with brain metastases who received icotinib treatment and kept satisfactory health-related quality of life for 1 year.

• 出版日期2015